| Description | Bemnifosbuvir hemisulfate (AT-527) is a potent inhibitor of HCV virus replication. |
| In vitro | The potent in vitro activity of AT-511, the free base of bemnifosbuvir hemisulfate, against several coronaviruses, including SARS-CoV-2. In normal human airway epithelial cells, the concentration of AT-511 required to inhibit replication of SARS-CoV-2 by 90% (EC90) was 0.47?μM, very similar to its EC90 against human coronavirus (HCoV)-229E, HCoV-OC43, and SARS-CoV in Huh-7 cells[1]. |
| In vivo | When given orally to rats and monkeys, bemnifosbuvir hemisulfate preferentially delivered high levels of AT-9010 in the liver in vivo.These favorable preclinical attributes support bemnifosbuvir hemisulfate may increase SVR rates[2]. |
| Target activity | SARS-CoV-2:0.47μM(EC90), HCV:5-28nM |
| Synonyms | AT-527 |
| molecular weight | 1261.15 |
| Molecular formula | C48H68F2N14O18P2S |
| CAS | 2241337-84-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 170 mg/mL (269.60 mM), Sonication is recommended. |
| References | 1. Good S S , Westover J , Jung K H , et al. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19[J]. Antimicrobial agents and chemotherapy, 65(4):e02479-20. 2. Good S S , Moussa A , Zhou X J , et al. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus[J]. PLoS ONE, 2020, 15(1):e0227104-. |